远程缺血预适应联合药物治疗或再灌注治疗对急性缺血性卒中的系统评价与Meta分析
该系统评价与Meta分析纳入22项随机对照试验共7657例急性缺血性卒中患者,评估远程缺血预适应(RIC)在不同治疗背景下的有效性与安全性。结果显示,接受药物治疗者RIC未改善mRS功能结局,但降低卒中复发(RR 0.63,95%CI 0.43-0.92,p=0.02)并降低随访NIHSS评分1.72分(p<0.00001),且未增加脑出血或死亡风险;接受静脉溶栓或机械取栓者未观察到RIC获益。
要点
- 药物治疗组RIC降低卒中复发(RR 0.63,95%CI 0.43-0.92,p=0.02)。
- 药物治疗组RIC随访NIHSS评分较对照降低1.72分(p<0.00001)。
- 静脉溶栓或机械取栓患者未观察到RIC获益。
核心结论
- 不适合再灌注治疗的缺血性卒中患者,RIC未影响mRS功能结局,但显著改善随访终点NIHSS评分并减少卒中复发,未增加脑出血或死亡风险。
- 接受静脉溶栓或机械取栓的患者未观察到RIC的获益。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Cochrane、Elsevier和Web of Science数据库自建库至2023年5月25日的所有语言文献。
- 纳入22项随机对照试验,共7657例患者。
- 主要结局为试验指定终点时间的改良Rankin量表(mRS)评分;次要结局为NIH卒中量表(NIHSS)变化和卒中事件复发;安全性结局为心血管事件、脑出血和死亡。
- 采用Cochrane风险评估工具评价文献质量,研究注册于PROSPERO(CRD42023430073)。
主要发现
- 与对照组相比,接受RIC的患者无论采用药物治疗、静脉溶栓(IVT)再灌注治疗还是机械取栓(MT),mRS功能结局均未改善。
- 药物治疗组中,接受RIC的患者卒中复发发生率降低(风险比0.63,95%CI 0.43-0.92,p=0.02),随访NIHSS评分较对照组降低1.72分(p<0.00001)。
- 静脉溶栓或药物治疗组未增加包括死亡或脑出血在内的不良事件风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Remote ischemic conditioning (RIC) is a low-cost, accessible, and noninvasive neuroprotective treatment strategy, but its efficacy and safety in acute ischemic stroke are controversial. With the publication of several randomized controlled trials (RCTs) and the recent results of the RESIST trial, it may be possible to identify the patient population that may (or may not) benefit from RIC. This systematic review and meta-analysis aims to evaluate the effectiveness and safety of RIC in patients with ischemic stroke receiving different treatments by pooling data of all randomized controlled studies to date. METHODS: We searched the PubMed, Embase, Cochrane, Elsevier, and Web of Science databases to obtain articles in all languages from inception until May 25, 2023. The primary outcome was the modified Rankin Scale (mRS) score at the specified endpoint time in the trial. The secondary outcomes were change in NIH Stroke Scale (NIHSS) and recurrence of stroke events. The safety outcomes were cardiovascular events, cerebral hemorrhage, and mortality. The quality of articles was evaluated through the Cochrane risk assessment tool. This study was registered in PROSPERO (CRD42023430073). RESULTS: There were 7,657 patients from 22 RCTs included. Compared with the control group, patients who received RIC did not have improved mRS functional outcomes, regardless of whether they received medical management, reperfusion therapy with intravenous thrombolysis (IVT), or mechanical thrombectomy (MT). In the medical management group, patients who received RIC had decreased incidence of stroke recurrence (risk ratio 0.63, 95% CI 0.43-0.92, p = 0.02) and lower follow-up NIHSS score by 1.72 points compared with the control group (p < 0.00001). There was no increased risk of adverse events including death or cerebral hemorrhage in the IVT or medical management group. DISCUSSION: In patients with ischemic stroke who are not eligible for reperfusion therapy, RIC did not affect mRS functional outcomes but significantly improved the NIHSS score at the follow-up endpoint and reduced stroke recurrence, without increasing the risk of cerebral hemorrhage or death. In patients who received IVT or MT, the benefit of RIC was not observed.
引用
- Li Q, Guo J, Chen HS, et al. Remote Ischemic Conditioning With Medical Management or Reperfusion Therapy for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurology. 2024. PMID: 38457772. doi:10.1212/WNL.0000000000207983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。